GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Analysis AS (FRA:8V8) » Definitions » Debt-to-Revenue

Genetic Analysis AS (FRA:8V8) Debt-to-Revenue : 0.49 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Genetic Analysis AS Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Genetic Analysis AS's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.17 Mil. Genetic Analysis AS's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.47 Mil. Genetic Analysis AS's annualized Revenue for the quarter that ended in Dec. 2023 was €1.32 Mil. Genetic Analysis AS's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 0.49.


Genetic Analysis AS Debt-to-Revenue Historical Data

The historical data trend for Genetic Analysis AS's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genetic Analysis AS Debt-to-Revenue Chart

Genetic Analysis AS Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
0.38 0.50 0.43 0.82 0.52

Genetic Analysis AS Quarterly Data
Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.66 0.42 0.44 0.57 0.49

Competitive Comparison of Genetic Analysis AS's Debt-to-Revenue

For the Diagnostics & Research subindustry, Genetic Analysis AS's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genetic Analysis AS's Debt-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Analysis AS's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Genetic Analysis AS's Debt-to-Revenue falls into.



Genetic Analysis AS Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Genetic Analysis AS's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.171 + 0.474) / 1.23
=0.52

Genetic Analysis AS's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.171 + 0.474) / 1.32
=0.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2023) Revenue data.


Genetic Analysis AS Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Genetic Analysis AS's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Genetic Analysis AS (FRA:8V8) Business Description

Traded in Other Exchanges
Address
Kabelgata 8, Oslo, NOR, 0580
Genetic Analysis AS is a research-driven diagnostic company dedicated to delivering innovative diagnostic solutions to the growing human microbiota market. It is providing a CE-marked gut microbiota analysis for testing bacterial imbalance in IBS and IBD patients.

Genetic Analysis AS (FRA:8V8) Headlines

No Headlines